Ana M. Molina

ORCID: 0000-0003-2025-9418

Also affiliated with Lander Institute, Presbyterian Hospital, Hospital Universitario de La Princesa, Weill Cornell Medicine

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 23 papers. Top paper: “Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591”.

Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

Journal of Clinical Oncology(2023)10.1200/jco.23.00573

N/A

2.6DataRank · unranked

69 citations

Charlene Thomas, Oliver Sartor, Michael Sun, Judith Stangl‐Kremser, Mahelia Bissassar +10 more

Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer

The Prostate(2021)10.1002/pros.24104

N/A

1.5DataRank · unranked

27 citations

Muhammad Junaid Niaz, Myrto Skafida, Seyed Ali Mosallaie, Charlene Thomas, Paul J. Christos +6 more

Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

Cancer(2020)10.1002/cncr.33148

N/A

1.2DataRank · unranked

38 citations

Yasser Ged, Chung‐Han Lee, Andrea Knežević, Ana M. Molina, Ying‐Bei Chen +13 more

Pilot Study of Hyperfractionated Dosing of Lutetium-177–Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer

The Oncologist(2020)10.1634/theoncologist.2020-0028

N/A

0.550DataRank · unranked

38 citations

Jaspreet S. Batra, Ryan D. Walsh, Marigdalia K. Ramirez‐Fort, Shankar Vallabhajosula, Yuliya Jhanwar +6 more

Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5015

N/A

0.515DataRank · unranked

30 citations

Michael Sun, Oliver Sartor, Charlene Thomas, Sharon Singh, Mahelia Bissassar +11 more

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5560

N/A

0.360DataRank · unranked

10 citations

Joseph R. Osborne, Escarleth Fernandez, Charlene Thomas, Muhammad Junaid Niaz, Amy Ciriaco +10 more

Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5018

N/A

0.360DataRank · unranked

10 citations

Michael Philip Sun, Jones T. Nauseef, Charlene Thomas, Sandra Huicochea Castellanos, Joseph Earl Thomas +12 more

Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.5074

N/A

0.312DataRank · unranked

7 citations

Charlene Thomas, Jones T. Nauseef, Oliver Sartor, Michael Philip Sun, Sandra Huicochea Castellanos +14 more

Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5100

N/A

0.269DataRank · unranked

5 citations

Joseph R. Osborne, Peter Gregos, Charlene Thomas, Mahelia Bissassar, Sharon Singh +14 more

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution

European Urology Oncology(2025)10.1016/j.euo.2025.05.014

N/A

0.269DataRank · unranked

5 citations

Marshall A. Diven, Brady Rippon, Christopher E. Barbieri, Jim C. Hu, Douglas S. Scherr +20 more

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.158

N/A

0.176DataRank · unranked

1 citations

Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez +10 more

The Interplay between Mutagenesis and Extrachromosomal DNA Shapes Urothelial Cancer Evolution

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.05.07.538753

N/A

0.165DataRank · unranked

2 citations

William F. Hooper, Timothy R. Chu, Heather Geiger, Jennifer Shelton, Minita Shah +21 more

Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.45

N/A

0.165DataRank · unranked

2 citations

Sukanya Goswami, Muhammad Junaid Niaz, Charlene Thomas, Paul J. Christos, Joseph R. Osborne +10 more

Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.120

N/A

0.104DataRank · unranked

1 citations

Michael Sun, Jones T. Nauseef, Muhammad Junaid Niaz, Dunya Imad, Paul J. Christos +11 more

Results from the prior treatment cohort of a phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.548

N/A

0DataRank · unranked

0 citations

Yasser Ged, Michael A Carducci, Ana M. Molina, Rahul Ravilla, Rachel Basiura +12 more

Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.114

N/A

0DataRank · unranked

24 citations

Joseph R. Osborne, Muhammad Junaid Niaz, Shankar Vallabhajosula, Panagiotis J. Vlachostergios, Charlene Thomas +9 more

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

Frontiers in Oncology(2021)10.3389/fonc.2021.630589

N/A

0DataRank · unranked

43 citations

Muhammad Junaid Niaz, Michael Sun, Seyed Ali Mosallaie, Charlene Thomas, Paul J. Christos +6 more

Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5055

N/A

0DataRank · unranked

0 citations

Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg +4 more

Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps216

N/A

0DataRank · unranked

9 citations

Joseph R. Osborne, Matthew C. Dallos, Jones T. Nauseef, Cora N. Sternberg, Peter Gregos +11 more

Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.037

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Michael Sun, Oliver Sartor, Sharon Singh, Mahelia Bissassar +15 more

Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.077

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Benedict Ho, Juana Martinez Zuloaga, Brian D. Gonzalez, Michael Sun +15 more

AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.4521

N/A

0DataRank · unranked

7 citations

Lindsay A. Renfro, Matthew R. Zibelman, Ana M. Molina, Mamta Parikh, Luke Pater +8 more

Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

Urologic Oncology Seminars and Original Investigations(2020)10.1016/j.urolonc.2020.05.028

N/A

0DataRank · unranked

49 citations

Muhammad Junaid Niaz, Young E. Whang, Arif Sheikh, Charlene Thomas, Paul J. Christos +8 more